About the Authors
- Luís Lima
-
Contributed equally to this work with: Luís Lima, Cristiana Gaiteiro, Andreia Peixoto
* E-mail: luis.carlos.lima@ipoporto.min-saude.pt
Affiliations Experimental Pathology and Therapeutics Group – Research Center, Portuguese Institute of Oncology of Porto (IPO-Porto), 4200-072, Porto, Portugal, i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), 4200-135 Porto, Portugal
- Cristiana Gaiteiro
-
Contributed equally to this work with: Luís Lima, Cristiana Gaiteiro, Andreia Peixoto
Affiliation Experimental Pathology and Therapeutics Group – Research Center, Portuguese Institute of Oncology of Porto (IPO-Porto), 4200-072, Porto, Portugal
- Andreia Peixoto
-
Contributed equally to this work with: Luís Lima, Cristiana Gaiteiro, Andreia Peixoto
Affiliations Experimental Pathology and Therapeutics Group – Research Center, Portuguese Institute of Oncology of Porto (IPO-Porto), 4200-072, Porto, Portugal, i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal
- Janine Soares
-
Affiliation Experimental Pathology and Therapeutics Group – Research Center, Portuguese Institute of Oncology of Porto (IPO-Porto), 4200-072, Porto, Portugal
- Manuel Neves
-
Affiliations Experimental Pathology and Therapeutics Group – Research Center, Portuguese Institute of Oncology of Porto (IPO-Porto), 4200-072, Porto, Portugal, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal
- Lúcio Lara Santos
-
Affiliations Experimental Pathology and Therapeutics Group – Research Center, Portuguese Institute of Oncology of Porto (IPO-Porto), 4200-072, Porto, Portugal, Health School of University of Fernando Pessoa, 4249-004, Porto, Portugal, Department of Surgical Oncology, Portuguese Institute of Oncology of Porto (IPO-Porto), 4200-072, Porto, Portugal
- José Alexandre Ferreira
-
Affiliations Experimental Pathology and Therapeutics Group – Research Center, Portuguese Institute of Oncology of Porto (IPO-Porto), 4200-072, Porto, Portugal, i3S - Instituto de Investigação e Inovação em Saúde, Universidade do Porto, Portugal, Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP), 4200-135 Porto, Portugal, Institute of Biomedical Sciences Abel Salazar (ICBAS), University of Porto, 4050-313 Porto, Portugal
Competing Interests
The authors have declared that no competing interests exist.
Author Contributions
Conceptualization: LL LLS JAF. Formal analysis: LL. Funding acquisition: LLS JAF. Investigation: JS MN AP CG. Methodology: LL AP CG. Project administration: LL LLS JAF. Resources: LLS JAF. Supervision: LLS JAF. Validation: MN. Writing – original draft: LL CG AP. Writing – review & editing: JAF LLS MN JS.